Pfizer beats Q3 expectations but sales teeter
29th October 2014
Pfizer managed to beat performance expectations for the third quarter, as results were given a leg up by solid demand in emerging markets (up 9%) and strong sales of its cancer drugs, which grew 17%
The drug giant booked earnings of $2.67 billion, or $0.42 a share for the period, inching up from $2.59 billion, or $0.39 per share, a year ago, though last year’s standing was pulled down by restructuring costs.
Read more at source article: www.pharmatimes.com